News

ACOR

Opportunities for Tenbaggers in the Microcap Biotech Space

The Life Sciences Report | Equities.com |

Institutional investors are, by and large, unable to own shares in companies with market valuations of less than $100 million, which means most sellside analysts don't write research on very


Do the Math: Ram Selvaraju on the Appeal of Biotechs in Orphan Diseases

The Life Sciences Report | Equities.com |

To cast a spotlight on disruptive biotechnology stocks, Raghuram "Ram" Selvaraju of Aegis Capital Corp. taps his experience as a molecular biologist, preclinical investigator and


From Lab Bench to Bedside: David Lowe Brings Common Sense to Neuroscience Investing

The Life Sciences Report | Equities.com |

Billions of dollars have been spent chasing molecular targets in neurological diseases that now appear to be worthless. Effective therapies remain rare. But the market is enormous—and low


5 Stocks In a Downward Wedge That Analysts Like

Joel Anderson | Equities.com |

Technical analysis can be a fickle beast. No matter how good you get at reading charts and spotting patterns, your careful research can go right out the window in a moment if something major


Aegis Capital Is Changing the Way Investors Look at HealthCare Stocks

Equities Editors Desk | Equities.com |

For the entire furor surrounding the upcoming implementation of “Obamacare” at the start of next year, few have been able to advance anything that resembles a comprehensive assessment


Equities Sector Coverage: Wall Street Slides Lower on Growing Concerns

Sector Recap | Equities.com |

The Dow Jones Industrial Average declined to a day’s low at 12,583.41 then cut the day’s loss by more than a half. The NASDAQ declined to 2852.88 then rebounded to a day’s high at 2898.05,


Equities Sector Coverage: Late Surge Helps Market Grab Gains

Sector Recap | Equities.com |

The Dow Jones Industrial Average traded up from 11,965.23 up to 12,051.28 versus its 200-day simple moving average at 11,975 then declined to 11,880.69 before recovering above the 200-day into the


Sponsored Financial Content

Market Movers